AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarterContinued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 millionAVLAYAH recognized as the “Best Biotechnology Product” of 2026 by The Galien FoundationZafinofusp alfa advancing as Denali’s second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA)Five TransportVehicle™ (TV) ...